Overview Dividends

(SRPT) Sarepta Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8036071004

RNA Therapeutics, Duchenne Muscular Dystrophy, Gene Therapy, Rare Diseases

Biotechnology
Market Cap in USD: 2,458m

IPO / Inception: 1997-06-03
Return 12m vs S&P 500: -84.5%

EPS (Earnings per Share)

EPS CAGR: 6.20%
EPS Trend: 57.4%

Last SUE: 0.86
Qual. Beats: 1

Revenue

Rev. CAGR: 20.02%
Rev. Trend: 91.1%

Last SUE: 1.85
Qual. Beats: 5

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	91.4%
Value at Risk 5%th	90.3%
Relative Tail Risk	-39.92%

Reward TTM
Sharpe Ratio	-1.04
Alpha	-105.42
CAGR/Max DD	-0.46

Character TTM
Hurst Exponent	0.428
Beta	1.489
Beta Downside	1.511

Drawdowns 3y
Max DD	92.72%
Mean DD	39.03%
Median DD	26.18%

Description: SRPT Sarepta Therapeutics November 13, 2025

Sarepta Therapeutics (NASDAQ:SRPT) is a commercial-stage biopharma that specializes in RNA-targeted and gene-therapy approaches for ultra-rare neuromuscular disorders, principally Duchenne muscular dystrophy (DMD).

Its approved portfolio includes EXONDYS 51, VYONDYS 53, and AMONDYS 45-exon-skipping antisense oligonucleotides that restore dystrophin production in mutation-specific DMD sub-populations-and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.

The pipeline extends beyond DMD with SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and a suite of collaborative programs with partners such as Roche, Arrowhead, Dyno Therapeutics, and academic institutions.

Key recent metrics (Q4 2023) show total revenue of $258 million, driven largely by EXONDYS 51 sales, a net loss of $115 million, and cash & cash equivalents of $1.2 billion, giving the company roughly 18 months of runway at current burn rates.

Sector-wide forces that materially affect Sarepta’s outlook include escalating pricing power for one-time gene therapies (average US list price > $2 billion), expanding payer frameworks for rare-disease treatments, and the FDA’s accelerated approval pathways that can shorten time-to-market for novel exon-skipping agents.

For a deeper, data-driven valuation of SRPT’s risk-adjusted upside, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-271.5m TTM) > 0 and > 6% of Revenue (6% = 144.8m TTM)

FCFTA -0.11 (>2.0%) and ΔFCFTA 2.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 74.61% (prev 121.1%; Δ -46.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.07 (>3.0%) and CFO -244.6m > Net Income -271.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 2.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (100.2m) change vs 12m ago -0.21% (target <= -2.0% for YES)

Gross Margin 76.25% (prev 85.92%; Δ -9.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 68.06% (prev 45.57%; Δ 22.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -10.58 (EBITDA TTM -180.7m / Interest Expense TTM 21.8m) >= 6 (WARN >= 3)

Altman Z'' -3.63

(A) 0.52 = (Total Current Assets 2.72b - Total Current Liabilities 921.4m) / Total Assets 3.49b

(B) -1.33 = Retained Earnings (Balance) -4.64b / Total Assets 3.49b

warn (B) unusual magnitude: -1.33 — check mapping/units

(D) -2.14 = Book Value of Equity -4.64b / Total Liabilities 2.17b

Total Rating: -3.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.23

1. Piotroski 2.0pt

2. FCF Yield -13.61%

3. FCF Margin -16.11%

4. Debt/Equity 0.95

5. Debt/Ebitda -3.53

6. ROIC - WACC (= -16.54)%

7. RoE -20.31%

8. Rev. Trend 91.11%

9. EPS Trend 57.39%

What is the price of SRPT shares?

As of January 09, 2026, the stock is trading at USD 23.15 with a total of 3,063,587 shares traded.
Over the past week, the price has changed by +8.63%, over one month by +5.90%, over three months by -0.98% and over the past year by -81.67%.

Is SRPT a buy, sell or hold?

Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.

Strong Buy: 14
Buy: 8
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SRPT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	20.6	-11%
Analysts Target Price	20.6	-11%
ValueRay Target Price	23.8	2.6%

SRPT Fundamental Data Overview January 09, 2026

P/E Forward = 18.9036
P/S = 1.0185
P/B = 1.8622
P/EG = 159.25
Beta = 0.479
Revenue TTM = 2.41b USD
EBIT TTM = -230.4m USD
EBITDA TTM = -180.7m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 637.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.86b USD (2.46b + Debt 1.25b - CCE 851.0m)
Interest Coverage Ratio = -10.58 (Ebit TTM -230.4m / Interest Expense TTM 21.8m)
FCF Yield = -13.61% (FCF TTM -388.8m / Enterprise Value 2.86b)
FCF Margin = -16.11% (FCF TTM -388.8m / Revenue TTM 2.41b)
Net Margin = -11.25% (Net Income TTM -271.5m / Revenue TTM 2.41b)
Gross Margin = 76.25% ((Revenue TTM 2.41b - Cost of Revenue TTM 573.2m) / Revenue TTM)
Gross Margin QoQ = 62.25% (prev 75.04%)
Tobins Q-Ratio = 0.82 (Enterprise Value 2.86b / Total Assets 3.49b)
Interest Expense / Debt = 0.61% (Interest Expense 7.57m / Debt 1.25b)
Taxrate = 7.27% (-14.1m / -194.0m)
NOPAT = -213.7m (EBIT -230.4m * (1 - 7.27%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 2.72b / Total Current Liabilities 921.4m)
Debt / Equity = 0.95 (Debt 1.25b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -3.53 (negative EBITDA) (Net Debt 637.1m / EBITDA -180.7m)
Debt / FCF = -1.64 (negative FCF - burning cash) (Net Debt 637.1m / FCF TTM -388.8m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.66% (Net Income -271.5m / Total Assets 3.49b)
RoE = -20.31% (Net Income TTM -271.5m / Total Stockholder Equity 1.34b)
RoCE = -9.71% (EBIT -230.4m / Capital Employed (Equity 1.34b + L.T.Debt 1.04b))
RoIC = -8.72% (negative operating profit) (NOPAT -213.7m / Invested Capital 2.45b)
WACC = 7.81% (E(2.46b)/V(3.71b) * Re(11.50%) + D(1.25b)/V(3.71b) * Rd(0.61%) * (1-Tc(0.07)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.57%
Fair Price DCF = unknown (Cash Flow -388.8m)
EPS Correlation: 57.39 | EPS CAGR: 6.20% | SUE: 0.86 | # QB: 1
Revenue Correlation: 91.11 | Revenue CAGR: 20.02% | SUE: 1.85 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=-0.047 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=2.77 | Chg30d=-0.528 | Revisions Net=-1 | Growth EPS=+238.5% | Growth Revenue=-25.3%

Additional Sources for SRPT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle